Antimicrobial susceptibility testing for Helicobacter pylori comes of age

Affiliations

¹ School of Medicine, Trinity College Dublin, Dublin 2, Ireland. Electronic address: colmomorain@rcpi.ie.
² School of Medicine, Trinity College Dublin, Dublin 2, Ireland.

Comment

Colm O'Morain et al. Lancet Gastroenterol Hepatol. 2023 Jul.

. 2023 Jul;8(7):593-595.

doi: 10.1016/S2468-1253(23)00113-9. Epub 2023 May 10.

¹ School of Medicine, Trinity College Dublin, Dublin 2, Ireland. Electronic address: colmomorain@rcpi.ie.
² School of Medicine, Trinity College Dublin, Dublin 2, Ireland.

No abstract available

Conflict of interest statement

We declare no competing interests.

Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials.
Chen MJ, Chen PY, Fang YJ, Bair MJ, Chen CC, Chen CC, Yang TH, Lee JY, Yu CC, Kuo CC, Chiu MC, Chou CK, Chen CY, Hu WH, Tsai MH, Hsu YC, Shun CT, Luo JC, Lin JT, El-Omar EM, Wu MS, Liou JM; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Chen MJ, et al. Lancet Gastroenterol Hepatol. 2023 Jul;8(7):623-634. doi: 10.1016/S2468-1253(23)00097-3. Epub 2023 May 10. Lancet Gastroenterol Hepatol. 2023. PMID: 37178702 Clinical Trial.